Fujitani Kazumasa, Yang Han-Kwang, Kurokawa Yukinori, Park Do Joong, Tsujinaka Toshimasa, Park Byung-Joo, Fukuda Haruhiko, Noh Sung Hoon, Boku Narikazu, Bang Yung-Jue, Sasako Mitsuru, Lee Jong-Inn
Department of Surgery, National Osaka Medical Center, 2-1-14 Hoenzaka, Chuo-ku, Osaka 540-0006, Japan.
Jpn J Clin Oncol. 2008 Jul;38(7):504-6. doi: 10.1093/jjco/hyn058. Epub 2008 Jul 9.
A randomized controlled trial has started in both Japan and Korea to evaluate the role of gastrectomy in the management of incurable advanced gastric cancer (AGC). Patients with AGC diagnosed as having a single non-curable factor are randomized to gastrectomy plus chemotherapy or chemotherapy alone. Surgeons at 33 specialized centers in Japan and at 15 high-volume hospitals in Korea will recruit 330 patients. Primary end-point is overall survival, and secondary end-points are progression-free survival and adverse events associated with either gastrectomy or chemotherapy.
日本和韩国都已启动一项随机对照试验,以评估胃切除术在不可治愈的晚期胃癌(AGC)治疗中的作用。被诊断为具有单一不可治愈因素的AGC患者被随机分为接受胃切除术加化疗或单纯化疗两组。日本33个专业中心和韩国15家大型医院的外科医生将招募330名患者。主要终点是总生存期,次要终点是无进展生存期以及与胃切除术或化疗相关的不良事件。